Cite

    D'Haens, G., Beaton, M., Bossuyt, P., Dotan, I., Sands, B., Sugimoto, K., Neimark, E., Song, A., Wallace, K., Zhou, Q., Kligys, K., & Ferrante, M. (n.d.). p544 Patients with moderate to severe Crohn's disease with and without prior biologic failure demonstrated improved clinical outcomes with risankizumab: Results from phase 3 induction and maintenance trials. Journal of Crohn's and colitis, 16, i491. http://access.bl.uk/ark:/81055/vdc_100150515167.0x00000d